---
title: "Gilead Sciences CEO Daniel O'Day Sells $35.6M in GILD Stock — Four Insiders Unload $42M"
type: news
slug: gilead-ceo-oday-sells-35m-gild-4-insiders-42m-feb-2026
canonical_url: https://13finsight.com/news/gilead-ceo-oday-sells-35m-gild-4-insiders-42m-feb-2026
published_at: 2026-02-28T20:58:01.626Z
updated_at: 2026-02-28T20:58:03.266Z
author: Alex Rivera
author_title: Breaking News Editor
author_url: https://13finsight.com/authors/alex-rivera
word_count: 454
locale: en
source: 13F Insight
---

# Gilead Sciences CEO Daniel O'Day Sells $35.6M in GILD Stock — Four Insiders Unload $42M

> Gilead Sciences CEO Daniel O'Day sold $35.6M in GILD across 5 transactions, while three other insiders added $6.4M. CFO Dickinson's $58.9M career sales lead the group.

Gilead Sciences Chairman and CEO Daniel O'Day sold $35.6 million in GILD stock across 5 transactions in early 2026 — his largest selling window on record. Three other insiders added $6.4 million, bringing total insider selling to $42.02 million. Four Insiders, $42M Insider Title Transactions Value Shares After Career Sales Daniel O'Day Chairman & CEO 5 $35.60M 556,698 $26.3M Johanna Mercier Chief Comm & Corp Aff Officer 5 $5.06M 103,221 $18.0M Andrew Dickinson Chief Financial Officer 2 $0.74M 150,503 $58.9M Jeffrey Bluestone Director 1 $0.62M 8,920 $2.5M Total: 4 insiders $42.02M CEO O'Day's Record Sale Daniel O'Day's $35.6 million sale actually exceeds his prior career total of $26.3 million — meaning this single selling window more than doubled his lifetime insider proceeds. He retains 556,698 shares worth approximately $62 million, so his remaining stake is still substantial. O'Day joined Gilead as CEO in 2019 from Roche, inheriting a company in transition from its hepatitis C blockbuster era to a more diversified portfolio including HIV, oncology, and inflammation. His decision to sell $35.6M now — significantly more than any prior window — suggests a significant reassessment of his personal risk allocation. CFO Dickinson: $58.9M Career Seller CFO Andrew Dickinson is the quiet monster on this list. His $58.9 million in career sales far exceeds the CEO's cumulative total — making him one of the most prolific insider sellers in big pharma. His $740K sale in this round is modest relative to his history, but the career context tells the story: the person who manages Gilead's finances has been consistently monetizing for years. Dickinson retains 150,503 shares (~$17M) — less than 30% of what he's sold over his career. Chief Communications Officer Mercier: $18M Career Johanna Mercier's $5.06M sale adds to her $18M career total. For a communications executive, $18M in lifetime insider sales is notable — she's monetized more than many C-suite leaders at smaller companies ever accumulate. Gilead at ~$112: The HIV/Oncology Giant Gilead Sciences is one of the world's largest biopharmaceutical companies, with dominant franchises in HIV treatment (Biktarvy), cell therapy (Yescarta), and a growing oncology pipeline. At ~$112 per share, the stock trades at approximately 12x forward earnings — a reasonable valuation by pharma standards. CEO doubled his career total in one shot: $35.6M vs $26.3M prior CFO is the biggest career seller: $58.9M lifetime 4 insiders, $42M total: Concentrated selling from the top Combined career: $105.7M from these four insiders For GILD investors, the CEO's record sale is the headline. When the person running a $140 billion pharma company sells more stock in one window than in his entire prior tenure combined, it's a signal worth considering — especially from the leader whose compensation is tied to the stock's future performance.

---

Source: 13F Insight — https://13finsight.com/news/gilead-ceo-oday-sells-35m-gild-4-insiders-42m-feb-2026
Author: Alex Rivera — https://13finsight.com/authors/alex-rivera
Last updated: 2026-02-28T20:58:03.266Z